Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Wilding · SciRah

Researcher profile · Semantic Scholar

J. Wilding

Share profile

J. Wilding — researcher profile on SciRah

h-index: 39
Works: 255
Citations: 19K

Most-cited papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon +17 more
2019New England Journal of Medicine4,872 citations Open access
Semantic Scholar
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
J. Wilding, R. Batterham, S. Calanna, M. Davies +10 more
2021New England Journal of Medicine3,682 citations Open access
Semantic Scholar
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
J. Wilding, R. Batterham, Melanie J. Davies, L. V. van Gaal +10 more
2022Diabetes, obesity and metabolism1,008 citations Open access
Semantic Scholar
Economic impacts of overweight and obesity: current and future estimates for 161 countries
Adeyemi Okunogbe, R. Nugent, G. Spencer, Jaynaide Powis +2 more
2022BMJ Global Health662 citations Open access
Semantic Scholar
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
M. Kosiborod, M. Cavender, A. Fu, J. Wilding +10 more
2017Circulation585 citations Open access
Semantic Scholar
Economic impacts of overweight and obesity: current and future estimates for eight countries
Adeyemi Okunogbe, R. Nugent, G. Spencer, J. Ralston +1 more
2021BMJ Global Health358 citations Open access
Semantic Scholar
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation.
F. Lopez-Jimenez, W. Almahmeed, H. Bays, A. Cuevas +7 more
2022European Journal of Preventive Cardiology311 citations Open access
Semantic Scholar
New insights into the treatment of obesity
M. Blüher, Mohini Aras, L. Aronne, R. Batterham +6 more
2023Diabetes, obesity and metabolism151 citations Open access
Semantic Scholar
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
S. Wiviott, I. Raz, Marc P. Bonaca, Ofri Mosenzon +12 more
2018American Heart Journal145 citations
Semantic Scholar
DECLARE‐TIMI 58: Participants’ baseline characteristics
I. Raz, Ofri Mosenzon, M. Bonaca, A. Cahn +11 more
2018Diabetes, obesity and metabolism114 citations
Semantic Scholar
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
J. Wilding, Kevin Fernando, N. Milne, M. Evans +7 more
2018Diabetes Therapy83 citations Open access
Semantic Scholar
Time for a new obesity narrative.
J. Ralston, H. Brinsden, K. Buse, V. Candeias +14 more
2018The Lancet64 citations Open access
Semantic Scholar
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
E. Brown, J. Wilding, U. Alam, T. Barber +2 more
2020Annals medicus63 citations Open access
Semantic Scholar
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58
Thomas A. Zelniker, D. Morrow, Ofri Mosenzon, Erica L. Goodrich +14 more
2020European Journal of Heart Failure55 citations Open access
Semantic Scholar
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
J. Wilding, Thomas Godec, K. Khunti, S. Pocock +6 more
2018BMC Medicine50 citations Open access
Semantic Scholar
Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58
A. Cahn, S. Wiviott, Ofri Mosenzon, S. Murphy +14 more
2020Diabetes, obesity and metabolism48 citations Open access
Semantic Scholar
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes
Nicola L. Harman, J. Wilding, D. Curry, James Harris +6 more
2019BMJ Open Diabetes Research & Care48 citations Open access
Semantic Scholar
Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management
J. Wilding, N. Zourikian, M. D. Di Minno, K. Khair +4 more
2018Obesity Reviews47 citations Open access
Semantic Scholar
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A. Zelniker, I. Raz, O. Mosenzon, J. Dwyer +12 more
2021JAMA cardiology46 citations Open access
Semantic Scholar
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Amar Ali, S. Bain, D. Hicks, Phillip Newland Jones +7 more
2019Diabetes Therapy46 citations Open access
Semantic Scholar
Medication use for the treatment of diabetes in obese individuals
J. Wilding
2017Diabetologia42 citations Open access
Semantic Scholar
Realising the full potential of data-enabled trials in the UK: a call for action
M. Sydes, Y. Barbáchano, L. Bowman, T. Denwood +24 more
2021BMJ Open41 citations Open access
Semantic Scholar
Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence
P. McEwan, H. Bennett, K. Khunti, J. Wilding +5 more
2020Diabetes, obesity and metabolism41 citations
Semantic Scholar
GLP-1 as a target for therapeutic intervention.
S. Rajeev, J. Wilding
2016Current opinion in pharmacology (Print)40 citations
Semantic Scholar
SGLT2 inhibitors and urinary tract infections
J. Wilding
2019Nature Reviews Endocrinology36 citations
Semantic Scholar
DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
Remo H M Furtado, M. Bonaca, I. Raz, Thomas A. Zelniker +14 more
2019Journal of the American College of Cardiology34 citations Open access
Semantic Scholar
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update
Martha Nicholson, Randa Ghazal Asswad, J. Wilding
2021Expert Opinion on Pharmacotherapy33 citations Open access
Semantic Scholar
Combination therapy for obesity
J. Wilding
2017Journal of Psychopharmacology33 citations
Semantic Scholar
Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
L. Johansson, P. Hockings, E. Johnsson, Nalina Dronamraju +3 more
2020Diabetes, obesity and metabolism30 citations Open access
Semantic Scholar
Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study
J. Wilding, C. Bailey, U. Rigney, B. Blak +2 more
2016Diabetes Therapy29 citations Open access
Semantic Scholar
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
J. Wilding, Clifford J. Bailey, U. Rigney, B. Blak +2 more
2017Primary Care Diabetes28 citations
Semantic Scholar
Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction
R. Ashrafi, P. Modi, A. Oo, D. Pullan +7 more
2017Experimental Physiology23 citations Open access
Semantic Scholar
Exercise in Obesity—the Role of Technology in Health Services: Can This Approach Work?
L. Dobbie, A. Tahrani, U. Alam, J. James +2 more
2021Current Obesity Reports22 citations Open access
Semantic Scholar
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
J. Wilding, M. Evans, Kevin Fernando, J. Górriz +12 more
2022Diabetes Therapy19 citations Open access
Semantic Scholar
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
N. Freemantle, D. Mauricio, A. Giaccari, T. Bailey +16 more
2019Current Medical Research and Opinion19 citations Open access
Semantic Scholar
Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis
R. Ashrafi, Marianne Yon, L. Pickavance, Joseph Yanni Gerges +6 more
2016Journal of Obesity18 citations Open access
Semantic Scholar
Short-Term Physical Inactivity Induces Endothelial Dysfunction
Kelly A. Bowden Davies, Juliette A. Norman, A. Thompson, Katie L. Mitchell +6 more
2021Frontiers in Physiology16 citations Open access
Semantic Scholar
SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials
Nicola L. Harman, R. James, J. Wilding, P. Williamson +1 more
2017Trials16 citations Open access
Semantic Scholar
Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity
A. Jackson-Morris, R. Nugent, J. Ralston, Olivia Barata Cavalcanti +1 more
2020Global Health Action14 citations Open access
Semantic Scholar
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
O. Schnell, T. Battelino, R. Bergenstal, A. L. Birkenfeld +32 more
2023Cardiovascular Diabetology12 citations Open access
Semantic Scholar
244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial
I. Raz, S. Wiviott, Ilan Yanuv, Aliza Rozenberg +15 more
2019Diabetes12 citations
Semantic Scholar
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
D. Papamargaritis, W. Al-Najim, Jonathan Lim, J. Crane +7 more
2020BMJ Open11 citations Open access
Semantic Scholar
Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes
J. Wilding, P. Hockings, E. Johnsson, Jill Maaske +2 more
2018Diabetes11 citations
Semantic Scholar
Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set
Nicola L. Harman, J. Wilding, D. Curry, James Harris +7 more
2018Trials11 citations Open access
Semantic Scholar
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Dalal Y Al-Bazz, J. Wilding
2020Future Cardiology10 citations
Semantic Scholar
Age no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials
D. Rubino, R. Coelho, S. Kahan, R. Kushner +4 more
2018XXI I Congresso Brasileiro de Nutrologia10 citations Open access
Semantic Scholar
Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome.
J. Shillito, J. Lea, S. Tierney, J. Cleator +2 more
2018Appetite10 citations
Semantic Scholar
Semaglutide treatment and renal function in the SUSTAIN 6 trial
S. Jacob, R. Silver, J. Gumprecht, T. Vilsbøll +4 more
2018Diabetologie und Stoffwechsel10 citations
Semantic Scholar
A group-based behavioural intervention for weight management (PROGROUP) versus usual care in adults with severe obesity: a feasibility randomised controlled trial protocol
D. Swancutt, M. Tarrant, Wendy Ingram, Sarah Baldrey +25 more
2022Pilot and Feasibility Studies8 citations Open access
Semantic Scholar
A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
E. Brown, M. Wilton, V. Sprung, J. Harrold +8 more
2021BMJ Open8 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Wiviott×8
Invite
S. Wiviott — researcher profile on SciRah
I. Raz×8
Invite
I. Raz — researcher profile on SciRah
Lawrence A Leiter×8
Invite
Lawrence A Leiter — researcher profile on SciRah
A. Langkilde×8
Invite
A. Langkilde — researcher profile on SciRah

×8

Invite

M. Sabatine — researcher profile on SciRah

Ofri Mosenzon×7

Invite

Ofri Mosenzon — researcher profile on SciRah

Deepak L. Bhatt×7

Invite

Deepak L. Bhatt — researcher profile on SciRah

Invite

A. Cahn — researcher profile on SciRah

Thomas A. Zelniker×5

Invite

Thomas A. Zelniker — researcher profile on SciRah

M. Fredriksson×5

Invite

M. Fredriksson — researcher profile on SciRah

Invite

S. Murphy — researcher profile on SciRah

Darren K Mcguire×4

Invite

Darren K Mcguire — researcher profile on SciRah